over that male: female ratio time. 1:1.1. Methodology not well described. Limited applicability to Australian setting due to Japanese subjects. Sharma () Level III-2 Some Subjects were Inclusion criteria were aged 5.7%≥ HbA1c 5.6 mmol/L≥ FPG Limited California, likelihood of African-American years, BMI at or above 85th HbA1c ≥6.5% FPG ≥7.0 mmol/L 3x3 table Baseline bias as children with BMI at percentile; exclusion criteria FPG USA ≤6.4% <7.0 mmol/L analysis of participants or above 85th ≥120 mg/dL, other metabolic disease participants in a recruited percentile; n= 172 or taking medications known to affect community-based through children, mean age study outcomes. lifestyle modification community, boys 9.96 years, girls program to reduce not from 9.80 years; 41% risk of type 2 referral. males. diabetes. Limited applicability to Australian setting as all children. Yesiltepe Level III-2 Level of bias N=106 obese or No inclusion or exclusion criteria HbA1c Not 100 mg/dL≥ FPG ROC Mutlu () and overweight children described. ≥5.5% reported FPG ≥126 mg/dL; analysis Chart review of Kocaeli, applicability who underwent OGT <126 mg/dL; children who 2hPG Turkey unclear as testing; mean age underwent OGT 140 mg/dL≥ ≥200 mg/dL population 13.4 ± 2.6 years, testing between Feb 2hPG and other range 7–18 years, 2010 and Feb 2011. <200 mg/dL methodology 33% male. not well described.
over that time. Methodology not well described. Limited applicability to Australian setting due to Japanese subjects. male: female ratio 1:1.1. Sharma () California, USA Level III-2 Baseline analysis of participants in a community-based lifestyle modification program to reduce risk of type 2 diabetes. Some likelihood of bias as participants recruited through community, not from referral. Limited applicability to Australian setting as all children. Subjects were African-American children with BMI at or above 85th percentile; n= 172 children, mean age boys 9.96 years, girls 9.80 years; 41% males. Inclusion criteria were aged years, BMI at or above 85th percentile; exclusion criteria FPG ≥120 mg/dL, other metabolic disease or taking medications known to affect study outcomes. 5.7%≥ HbA1c ≤6.4% HbA1c ≥6.5% 5.6 mmol/L≥ FPG <7.0 mmol/L FPG ≥7.0 mmol/L Limited 3x3 table Yesiltepe Mutlu () Kocaeli, Turkey Level III-2 Chart review of children who underwent OGT testing between Feb 2010 and Feb 2011. Level of bias and applicability unclear as population and other methodology not well described. N=106 obese or overweight children who underwent OGT testing; mean age 13.4 ± 2.6 years, range 7–18 years, 33% male. No inclusion or exclusion criteria described. HbA1c ≥5.5% Not reported 100 mg/dL≥ FPG <126 mg/dL; 140 mg/dL≥ 2hPG <200 mg/dL FPG ≥126 mg/dL; 2hPG ≥200 mg/dL ROC analysis
1267-FinalContractedAssessmentReport-accessible.DOCX